| For: | Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014; 5(2): 125-133 [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v5/i2/125.htm |
| Number | Citing Articles |
| 1 |
Clémence Dubois, Robin Dufour, Pierre Daumar, Corinne Aubel, Claire Szczepaniak, Christelle Blavignac, Emmanuelle Mounetou, Frédérique Penault-Llorca, Mahchid Bamdad. Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines. Oncotarget 2017; 8(56) doi: 10.18632/oncotarget.20517
|
| 2 |
Sha Li, Yijing Wu, Fei Ding, Jiapei Yang, Jing Li, Xihui Gao, Chuan Zhang, Jing Feng. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale 2020; 12(19) doi: 10.1039/D0NR00523A
|
| 3 |
Wenxian Zheng, Shuyan Han, Shantong Jiang, Xiran He, Xiaohong Li, Huirong Ding, Minhua Cao, Pingping Li. Antitumor effects of Xi Huang pills on MDA‑MB‑231 cells in�vitro and in�vivo. Molecular Medicine Reports 2018; doi: 10.3892/mmr.2018.9203
|
| 4 |
Heba Azzam, Rasha Kamal, Hany El-Assaly, Lamiaa I. A. Metwally. The value of dynamic contrast-enhanced MRI in differentiating triple-negative breast cancer from other subtypes. Egyptian Journal of Radiology and Nuclear Medicine 2019; 50(1) doi: 10.1186/s43055-019-0118-4
|
| 5 |
Manal Amoury, Radoslav Mladenov, Thomas Nachreiner, Anh‐Tuan Pham, Dmitrij Hristodorov, Stefano Di Fiore, Wijnand Helfrich, Alessa Pardo, Georg Fey, Michael Schwenkert, Theophilus Thepen, Fabian Kiessling, Ahmad F. Hussain, Rainer Fischer, Katharina Kolberg, Stefan Barth. A novel approach for targeted elimination of CSPG4‐positive triple‐negative breast cancer cells using a MAP tau‐based fusion protein. International Journal of Cancer 2016; 139(4) doi: 10.1002/ijc.30119
|
| 6 |
Shahla Masood. The changing role of pathologists from morphologists to molecular pathologists in the era of precision medicine. The Breast Journal 2020; 26(1) doi: 10.1111/tbj.13728
|
| 7 |
Matloob Khushi, Christine L. Clarke, J. Dinny Graham. Bioinformatic analysis of cis-regulatory interactions between progesterone and estrogen receptors in breast cancer. PeerJ 2014; 2 doi: 10.7717/peerj.654
|
| 8 |
Catherine A. Powell, Mohd W. Nasser, Helong Zhao, Jacob C. Wochna, Xiaoli Zhang, Charles Shapiro, Konstantin Shilo, Ramesh K. Ganju. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability. Oncotarget 2015; 6(8) doi: 10.18632/oncotarget.3442
|
| 9 |
Daniel Dávila-González, Dong Soon Choi, Roberto R. Rosato, Sergio M. Granados-Principal, John G. Kuhn, Wen-Feng Li, Wei Qian, Wen Chen, Anthony J. Kozielski, Helen Wong, Bhuvanesh Dave, Jenny C. Chang. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer. Clinical Cancer Research 2018; 24(5) doi: 10.1158/1078-0432.CCR-17-1437
|
| 10 |
Asadoor Amirkhani Namagerdi, Danila d’Angelo, Francesca Ciani, Carmelina Antonella Iannuzzi, Francesco Napolitano, Luigi Avallone, Michelino De Laurentiis, Antonio Giordano. Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.563779
|
| 11 |
Silvia Cecilia Pacheco-Velázquez, Diana Xochiquetzal Robledo-Cadena, Ileana Hernández-Reséndiz, Juan Carlos Gallardo-Pérez, Rafael Moreno-Sánchez, Sara Rodríguez-Enríquez. Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell Phenotype. Molecular Pharmaceutics 2018; 15(6) doi: 10.1021/acs.molpharmaceut.8b00015
|
| 12 |
KeeSoo Nam, Seog-ho Son, Sunhwa Oh, Donghwan Jeon, Hyungjoo Kim, Dong-Young Noh, Sangmin Kim, Incheol Shin. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells. Oncotarget 2017; 8(22) doi: 10.18632/oncotarget.16208
|
| 13 |
Shang-Pen Huang, Pei-Yao Liu, Chih-Jung Kuo, Chi-Long Chen, Wei-Jiunn Lee, Yu-Hui Tsai, Yuan-Feng Lin. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer. Journal of Hematology & Oncology 2017; 10(1) doi: 10.1186/s13045-017-0481-4
|
| 14 |
Harold Nathan C Tan, Maria Belen E Tamayo, Regina T Edusma-Dy, Francisco Vicente F Lopez. A Retrospective Cohort Study on the Disease-Free Survival and Overall Survival of Patients with Stage I-III Triple-Negative Breast Cancer given Adjuvant Chemotherapy in the Makati Medical Center. Philippine Journal of Internal Medicine 2021; 59(3) doi: 10.65564/pjim.1918b46177
|
| 15 |
Hana Elshaflu, Snežana Bjelogrlić, Christian D. Muller, Tamara R. Todorović, Marko Rodić, Aleksandar Marinković, Nenad R. Filipović. Co(III) complex with (E)-2-(2-(pyridine-2-ylmethylene)hydrazinyl)-4-(4-tolyl)-1,3-thiazole: structure and activity against 2-D and 3-D cancer cell models. Journal of Coordination Chemistry 2016; 69(22) doi: 10.1080/00958972.2016.1232404
|
| 16 |
Kyung-Hee Chun, Jong Hoon Park, Siting Fan. Translational Research in Breast Cancer. Advances in Experimental Medicine and Biology 2017; 1026 doi: 10.1007/978-981-10-6020-5_4
|
| 17 |
M.A. O’Rorke, L.J. Murray, J.S. Brand, N. Bhoo-Pathy. The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients. Cancer Treatment Reviews 2016; 47 doi: 10.1016/j.ctrv.2016.05.001
|
| 18 |
Mahdieh Razmi, Azra Rabbani-Chadegani, Fatemeh Hashemi-Niasari, Parinaz Ghadam. Lithium chloride attenuates mitomycin C induced necrotic cell death in MDA-MB-231 breast cancer cells via HMGB1 and Bax signaling. Journal of Trace Elements in Medicine and Biology 2018; 48 doi: 10.1016/j.jtemb.2018.03.011
|
| 19 |
Padma P. Tadi Uppala, Elmer C. Rivera, Hyun J. Kwon, Sharon S. Lum. Serum Protein Signatures for Breast Cancer Detection in Treatment-Naïve African American Women Using Integrated Proteomics and Pattern Analysis. Sensors 2026; 26(2) doi: 10.3390/s26020403
|
| 20 |
Yubing Zhou, Chao Han, Duolu Li, Zujiang Yu, Fengmei Li, Feng Li, Qi An, Huili Bai, Xiaojian Zhang, Zhenfeng Duan, Quancheng Kan. Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth. Scientific Reports 2015; 5(1) doi: 10.1038/srep10433
|
| 21 |
Hua-Tao Liang, Feng-Ying Huang, Wei-Jing Xie, Ming-Hui Chen, Ri-Hong Wu, Shu-Zhen Dai, Wen-Tian Xu, Wu-Ping Zheng, Guang-Hong Tan. Penicilazaphilone C triggers ferroptosis in triple-negative breast cancer cells via the MDM2/p53/SLC7 A11/GPX4 pathway. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-02687-w
|
| 22 |
Aurore Claude-Taupin, Leïla Fonderflick, Thierry Gauthier, Laura Mansi, Jean-René Pallandre, Christophe Borg, Valérie Perez, Franck Monnien, Marie-Paule Algros, Marc Vigneron, Pascale Adami, Régis Delage-Mourroux, Paul Peixoto, Michael Herfs, Michaël Boyer-Guittaut, Eric Hervouet. ATG9A Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes. Cells 2018; 7(12) doi: 10.3390/cells7120248
|
| 23 |
Victoria A. Reid, Barbara Yang, Kyle Russo, Melina J. Sedano, Ramesh Choudhari, Enrique I. Ramos, Shrikanth S. Gadad. Molecular Effects of Glucose on MIR503HG-Regulated Genes in Triple-Negative Breast Cancer. British Journal of Biomedical Science 2025; 82 doi: 10.3389/bjbs.2025.15206
|
| 24 |
Alessandra Longo, Mariangela Librizzi, Irina Chuckowree, Christine Baltus, John Spencer, Claudio Luparello. Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells. Molecules 2015; 20(6) doi: 10.3390/molecules20069879
|
| 25 |
Kamal Ahmed, Alexey Koval, Jiabin Xu, Alexandre Bodmer, Vladimir L. Katanaev. Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor. Cancer Letters 2019; 449 doi: 10.1016/j.canlet.2019.02.018
|
| 26 |
Rittwika Bhattacharya, Koyel Banerjee, Nupur Mukherjee, Minakshi Sen, Ashis Mukhopadhyay. From molecular insight to therapeutic strategy: The holistic approach for treating triple negative breast cancer. Pathology - Research and Practice 2017; 213(3) doi: 10.1016/j.prp.2017.01.001
|
| 27 |
Shiva Sabzandam, Masoumeh Zahmatkeshan, Moein Adel, Mehrad Mehrdadian, Farzaneh Saliminia, Fariba Esmaeili. Investigating the therapeutic effect of folic acid conjugated ZnO nanoparticles on human triple negative breast cancer cell line. Zastita Materijala 2023; 64(2) doi: 10.5937/zasmat2302213S
|
| 28 |
XIANGNAN KONG, XIA DING, QIFENG YANG. Identification of multi-target effects of Huaier aqueous extract via microarray profiling in triple-negative breast cancer cells. International Journal of Oncology 2015; 46(5) doi: 10.3892/ijo.2015.2932
|
| 29 |
Tejaswini P. Reddy, Dong S. Choi, Ann C. Anselme, Wei Qian, Wen Chen, Johan Lantto, Ivan D. Horak, Michael Kragh, Jenny C. Chang, Roberto R. Rosato. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs . Breast Cancer Research 2020; 22(1) doi: 10.1186/s13058-020-01280-z
|
| 30 |
Meaghan Krohe, Yanni Hao, Roger E. Lamoureux, Nina Galipeau, Denise Globe, Catherine Foley, Iyar Mazar, Jeffrey Solomon, Alan L. Shields. Patient-Reported Outcomes in Metastatic Breast Cancer: A Review of Industry-Sponsored Clinical Trials. Breast Cancer: Basic and Clinical Research 2016; 10 doi: 10.4137/BCBCR.S39385
|
| 31 |
Gamze Guney Eskiler, Gulsah Cecener, Unal Egeli, Berrin Tunca. Triple negative breast cancer: new therapeutic approaches and BRCA status. APMIS 2018; 126(5) doi: 10.1111/apm.12836
|
| 32 |
Manuela Labbozzetta, Monica Notarbartolo, Paola Poma. Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View. International Journal of Molecular Sciences 2020; 21(9) doi: 10.3390/ijms21093070
|
| 33 |
Martin Vojtek, Clara B. Martins, Raquel Ramos, Sara Gomes Duarte, Isabel M. P. L. V. O. Ferreira, Ana L. M. Batista de Carvalho, M. Paula M. Marques, Carmen Diniz. Pd(II) and Pt(II) Trinuclear Chelates with Spermidine: Selective Anticancer Activity towards TNBC-Sensitive and -Resistant to Cisplatin. Pharmaceutics 2023; 15(4) doi: 10.3390/pharmaceutics15041205
|
| 34 |
S Cowherd, L D Miller, S A Melin, S Akman, S Isom, J Cole, A Pullikuth, J A Lawrence. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cancer Biology & Therapy 2015; 16(5) doi: 10.1080/15384047.2015.1026481
|
| 35 |
Dong Hwan Kim, Bokyung Sung, Jin-Ah Kim, Yong Jung Kang, Seong Yeon Hwang, Na-Lam Hwang, Hongsuk Suh, Yung Hyun Choi, Eunok Im, Hae Young Chung, Nam Deuk Kim. HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model. International Journal of Oncology 2017; 51(2) doi: 10.3892/ijo.2017.4058
|
| 36 |
H. Portha, C. Jankowski, M. Cortet, I. Desmoulins, E. Martin, V. Lorgis, L. Arnould, C. Coutant. Tumeurs localisées du sein triple négatives en 2016 : définitions et prise en charge. Gynécologie Obstétrique & Fertilité 2016; 44(9) doi: 10.1016/j.gyobfe.2016.06.014
|
| 37 |
Vladimir L. Katanaev, Artem Blagodatski, Jiabin Xu, Yuri Khotimchenko, Alexey Koval. Pharmacology of the WNT Signaling System. Handbook of Experimental Pharmacology 2021; 269 doi: 10.1007/164_2021_530
|
| 38 |
Onyinyechi Obidiro, Gantumur Battogtokh, Emmanuel O. Akala. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics 2023; 15(7) doi: 10.3390/pharmaceutics15071796
|
| 39 |
Yueren Fan, He Wang, Hongyu Zhang, Tianfei Ma, Yihang Zhao. Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation. Frontiers in Immunology 2025; 16 doi: 10.3389/fimmu.2025.1711415
|
| 40 |
Murugan Kalimutho, Kate Parsons, Deepak Mittal, J. Alejandro López, Sriganesh Srihari, Kum Kum Khanna. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends in Pharmacological Sciences 2015; 36(12) doi: 10.1016/j.tips.2015.08.009
|
| 41 |
Marina K. Ibragimova, Matvey M. Tsyganov, Nikolai V. Litviakov. Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype. Cancers 2021; 13(21) doi: 10.3390/cancers13215348
|
| 42 |
|
| 43 |
Haonan Li, Fanxing Xu, Gang Gao, Xiang Gao, Bo Wu, Chao Zheng, Peng Wang, Zhanlin Li, Huiming Hua, Dahong Li. Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer. Redox Biology 2020; 34 doi: 10.1016/j.redox.2020.101564
|
| 44 |
Muhammed Ihsan Han, Pınar Atalay, Guzide Satir-Basaran. The VEGF/VEGFR axis in triple-negative breast cancer: a comprehensive review of therapeutic strategies. Gene 2026; 1001 doi: 10.1016/j.gene.2026.150201
|
| 45 |
SEUNG-YOUN JUNG, JAE YOUN YI, MI-HYOUNG KIM, KYUNG-HEE SONG, SEONG-MOOK KANG, JIYEON AHN, SANG-GU HWANG, KY-YOUB NAM, JIE-YOUNG SONG. IM-412 inhibits the invasion of human breast carcinoma cells by blocking FGFR-mediated signaling. Oncology Reports 2015; 34(5) doi: 10.3892/or.2015.4249
|
| 46 |
Cassandre Yip, Pierre Foidart, Joan Somja, Alice Truong, Mehdi Lienard, Emilie Feyereisen, Hélène Schroeder, Stéphanie Gofflot, Anne-Françoise Donneau, Joëlle Collignon, Philippe Delvenne, Nor Eddine Sounni, Guy Jerusalem, Agnès Noël. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. British Journal of Cancer 2017; 116(6) doi: 10.1038/bjc.2017.23
|
| 47 |
Marc Damelin, Alexander Bankovich, Albert Park, Jorge Aguilar, Wade Anderson, Marianne Santaguida, Monette Aujay, Sarah Fong, Kiran Khandke, Virginia Pulito, Elana Ernstoff, Paul Escarpe, Jeffrey Bernstein, Marybeth Pysz, Wenyan Zhong, Erik Upeslacis, Judy Lucas, Justin Lucas, Timothy Nichols, Kathryn Loving, Orit Foord, Johannes Hampl, Robert Stull, Frank Barletta, Hadi Falahatpisheh, Puja Sapra, Hans-Peter Gerber, Scott J. Dylla. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. Clinical Cancer Research 2015; 21(18) doi: 10.1158/1078-0432.CCR-15-0695
|
| 48 |
Jiajing Chen, Yuenong Qin, Chenping Sun, Wei Hao, Shuai Zhang, Yi Wang, Juan Chen, Lixin Chen, Yiying Ruan, Sheng Liu. Clinical study on postoperative triple-negative breast cancer with Chinese medicine. Medicine 2018; 97(25) doi: 10.1097/MD.0000000000011061
|
| 49 |
Aleksandra K. Olow, Laura van ’t Veer, Denise M. Wolf. Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-07912-7
|
| 50 |
Hongxiang Li, Chunyue Zhao, Zhen Wang, Jinfeng Xing. Investigation of chrysin inhibition on free radical photopolymerization during the preparation of nanogels under green LED irradiation. Journal of Photochemistry and Photobiology A: Chemistry 2023; 438 doi: 10.1016/j.jphotochem.2022.114518
|
| 51 |
Fukai Wang, Xiang Song, Shuangshuang Ma, Chenyu Liu, Xiaohui SUN, Xinzhao Wang, Zhaoyun Liu, Dong Liang, Zhiyong Yu. The treatment role of Cyperus rotundus L. to triple-negative breast cancer cells. Bioscience Reports 2019; 39(6) doi: 10.1042/BSR20190502
|
| 52 |
Anna Wawruszak, Jarogniew Luszczki, Marta Halasa, Estera Okon, Sebastian Landor, Cecilia Sahlgren, Adolfo Rivero-Muller, Andrzej Stepulak. Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together. International Journal of Molecular Sciences 2021; 22(10) doi: 10.3390/ijms22105184
|
| 53 |
Keith O’Brien, Michelle C. Lowry, Claire Corcoran, Vanesa G. Martinez, Melissa Daly, Sweta Rani, William M. Gallagher, Marek W. Radomski, Roderick A.F. MacLeod, Lorraine O’Driscoll. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 2015; 6(32) doi: 10.18632/oncotarget.5192
|
| 54 |
Rania Hegazy, Heba Azzam. Value of apparent diffusion coefficient factor in correlation with the molecular subtypes, tumor grade, and expression of Ki-67 in breast cancer. Egyptian Journal of Radiology and Nuclear Medicine 2022; 53(1) doi: 10.1186/s43055-022-00881-2
|
| 55 |
Ming-juan Liao, Mei-na Ye, Rui-juan Zhou, Jia-yu Sheng, Hong-feng Chen, Min Li. Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple‐Negative Breast Cancer Xenografts. Evidence-Based Complementary and Alternative Medicine 2014; 2014(1) doi: 10.1155/2014/628712
|
| 56 |
XUHONG ZHU, QIN LI, SHUANG LI, BOTE CHEN, HAIDONG ZOU. HIF-1α decoy oligodeoxynucleotides inhibit HIF-1α signaling and breast cancer proliferation. International Journal of Oncology 2015; 46(1) doi: 10.3892/ijo.2014.2715
|
| 57 |
Renata Danielle Sicchieri, Willian Abraham da Silveira, Larissa Raquel Mouro Mandarano, Tatiane Mendes Gonçalves de Oliveira, Hélio Humberto Angotti Carrara, Valdair Francisco Muglia, Jurandyr Moreira de Andrade, Daniel Guimarães Tiezzi. ABCG2 is a potential marker of tumor-initiating cells in breast cancer. Tumor Biology 2015; 36(12) doi: 10.1007/s13277-015-3647-0
|
| 58 |
Magdalena Absmaier, Rudolf Napieralski, Tibor Schuster, Michaela Aubele, Axel Walch, Viktor Magdolen, Julia Dorn, Eva Gross, Nadia Harbeck, Aurelia Noske, Marion Kiechle, Manfred Schmitt. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. International Journal of Oncology 2018; doi: 10.3892/ijo.2018.4241
|
| 59 |
Xiao‐Lin Zhang, Na Liu, Shan‐Fan Weng, Hong‐Sheng Wang. Bisphenol A Increases the Migration and Invasion of Triple‐Negative Breast Cancer Cells via Oestrogen‐related Receptor Gamma. Basic & Clinical Pharmacology & Toxicology 2016; 119(4) doi: 10.1111/bcpt.12591
|
| 60 |
Sarita Das, Neha Tripathi, Sumit Siddharth, Anmada Nayak, Deepika Nayak, Chinmayee Sethy, Prasad V. Bharatam, Chanakya Nath Kundu. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Apoptosis 2017; 22(10) doi: 10.1007/s10495-017-1400-4
|
| 61 |
Nemany A.N. Hanafy, Stefano Leporatti, Maged A. El-Kemary. Extraction of chlorophyll and carotenoids loaded into chitosan as potential targeted therapy and bio imaging agents for breast carcinoma. International Journal of Biological Macromolecules 2021; 182 doi: 10.1016/j.ijbiomac.2021.03.189
|
| 62 |
Shahla Masood. Breast Cancer Subtypes: Morphologic and Biologic Characterization. Women's Health 2016; 12(1) doi: 10.2217/whe.15.99
|
| 63 |
Zining Jin, Wenqian Wang, Nan Jiang, Lei Zhang, Yiming Li, Xiaoyin Xu, Shouliang Cai, Liang Wei, Xuhong Liu, Guanglei Chen, Yizhen Zhou, Cheng Liu, Zhan Li, Feng Jin, Bo Chen, Ying-Jan Wang. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy. PLOS ONE 2015; 10(7) doi: 10.1371/journal.pone.0130286
|
| 64 |
Farhad Vesuna, Paul T. Winnard, Marise Heerma van Voss, Guus M. Bol, Natalie D. ter Hoeve, Paul J. van Diest, Venu Raman. Inhibition of DDX3 modulates immune signaling in aggressive breast cancers. Cancer Letters 2025; 634 doi: 10.1016/j.canlet.2025.218065
|
| 65 |
Hui Yao, Guangchun He, Shichao Yan, Chao Chen, Liujiang Song, Thomas J. Rosol, Xiyun Deng. Triple-negative breast cancer: is there a treatment on the horizon?. Oncotarget 2017; 8(1) doi: 10.18632/oncotarget.12284
|
| 66 |
Long Ge, Yan Tang, Qiu-Ning Zhang, Jin-Hui Tian, Xiao-Hu Wang, Dawid Pieper, Bei Pan, Lun Li, Juan Ling, Zhi-Tong Bing, Ke-Hu Yang. A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer. Oncotarget 2017; 8(35) doi: 10.18632/oncotarget.19102
|
| 67 |
Dulla Naveen Kumar, Aiswarya Chaudhuri, Udita Shiromani, Dinesh Kumar, Ashish Kumar Agrawal. An Investigation of In Vitro Anti-Cancer Efficacy of Dihydroartemisinin-Loaded Bovine Milk Exosomes Against Triple-Negative Breast Cancer. The AAPS Journal 2024; 26(5) doi: 10.1208/s12248-024-00958-y
|
| 68 |
Y. L. Xu, R. Yao, J. Li, Y. D. Zhou, F. Mao, B. Pan, Q. Sun. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer. Cancer Chemotherapy and Pharmacology 2017; 79(6) doi: 10.1007/s00280-017-3319-4
|
| 69 |
Zehedina Khatun, Md Nurunnabi, Md Nafiujjaman, Gerald R. Reeck, Haseeb A. Khan, Kwang Jae Cho, Yong-kyu Lee. A hyaluronic acid nanogel for photo–chemo theranostics of lung cancer with simultaneous light-responsive controlled release of doxorubicin. Nanoscale 2015; 7(24) doi: 10.1039/C5NR01075F
|
| 70 |
Hyosun Kim, Jihyoung Cho, Sun Young Kwon, Sun Hee Kang. Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma. Annals of Surgical Treatment and Research 2016; 90(1) doi: 10.4174/astr.2016.90.1.1
|
| 71 |
Hossam Taha Mohamed, Eslam A. El-Ghonaimy, Mohamed El-Shinawi, Mohamed Hosney, Martin Götte, Wendy A. Woodward, Tahani El-Mamlouk, Mona Mostafa Mohamed. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2. Toxicology and Applied Pharmacology 2020; 401 doi: 10.1016/j.taap.2020.115092
|
| 72 |
Hassan Y. Ebrahim, Mohamed M. Mohyeldin, Mohammad M. Hailat, Khalid A. El Sayed. (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies. Bioorganic & Medicinal Chemistry 2016; 24(22) doi: 10.1016/j.bmc.2016.09.032
|
| 73 |
Juan Garona, Marina Pifano, Maria B. Pastrian, Daniel E. Gomez, Giselle V. Ripoll, Daniel F. Alonso. Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models. Clinical & Experimental Metastasis 2016; 33(6) doi: 10.1007/s10585-016-9799-5
|
| 74 |
Ke Wang, Xue Zhu, Kai Zhang, Yongxiang Yin, Yu Chen, Ting Zhang. Interleukin‐6 contributes to chemoresistance in MDA‐MB‐231 cells via targeting HIF‐1α. Journal of Biochemical and Molecular Toxicology 2018; 32(3) doi: 10.1002/jbt.22039
|
| 75 |
Solange Bayard, Genevieve Fasano, Yalei Chen, Melissa Davis, Michele Drotman, Jessica Bensenhaver, Alexander Swistel, Rache Simmons, Jennifer Marti, Lisa Newman. Screening mammography mitigates breast cancer disparities through early detection of triple negative breast cancer. Clinical Imaging 2021; 80 doi: 10.1016/j.clinimag.2021.08.013
|
| 76 |
Francisca Guardiola-Serrano, Roberto Beteta-Göbel, Raquel Rodríguez-Lorca, Maitane Ibarguren, David J. López, Silvia Terés, María Alonso-Sande, Mónica Higuera, Manuel Torres, Xavier Busquets, Pablo V. Escribá. The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt. Oncotarget 2019; 10(26) doi: 10.18632/oncotarget.26824
|
| 77 |
Aixue Li, Yunan Zhao, Yixiu Li, Liangdi Jiang, Yongwei Gu, Jiyong Liu. Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles. Drug Delivery 2021; 28(1) doi: 10.1080/10717544.2021.1938757
|
| 78 |
Mohammad Nafees Ansari, Jasleen Kaur, Ali Khan, Animesh Kar, Rajeshwari Tripathi, Dolly Jain, Bharti Aggarwal, Avinash Bajaj, Arnab Mukhopadhyay, Ujjaini Dasgupta. Localized Hydrogel-Mediated Docetaxel-Carboplatin Combination Chemotherapy Targets Ganglioside Metabolism to Mitigate Tumor Progression. ACS Pharmacology & Translational Science 2025; 8(11) doi: 10.1021/acsptsci.5c00203
|
| 79 |
Yu Ran Lee, Myoung Soo Park, Hee Kyoung Joo, Ki Mo Kim, Jeryong Kim, Byeong Hwa Jeon, Sunga Choi. Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-27025-9
|
| 80 |
Janine Jung, Vinona Wagner, Cindy Körner. microRNAS in Therapy Resistance of Breast Cancer. EMJ Oncology 2016; doi: 10.33590/emjoncol/10311296
|
| 81 |
Sergio Andrés Torres-Pérez, María del Pilar Ramos-Godínez, Eva Ramón-Gallegos. Glycosylated one-step PAMAM dendrimers loaded with methotrexate for target therapy in breast cancer cells MDA-MB-231. Journal of Drug Delivery Science and Technology 2020; 58 doi: 10.1016/j.jddst.2020.101769
|
| 82 |
Sabine Heublein, Doris Mayr, Alfons Meindl, Alexandra Kircher, Udo Jeschke, Nina Ditsch. Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis. Journal of Experimental & Clinical Cancer Research 2017; 36(1) doi: 10.1186/s13046-017-0517-1
|
| 83 |
Wenxian Zheng, Shuyan Han, Shantong Jiang, Lina Pang, Xiaohong Li, Xijuan Liu, Minhua Cao, Pingping Li. Multiple effects of Xihuang pill aqueous extract on the Hs578T triple-negative breast cancer cell line. Biomedical Reports 2016; 5(5) doi: 10.3892/br.2016.769
|
| 84 |
Anna Wawruszak, Jarogniew J. Luszczki, Joanna Kalafut, Karolina Okla, Marta Halasa, Adolfo Rivero-Muller, Andrzej Stepulak. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity—An Isobolographic Analysis. International Journal of Molecular Sciences 2019; 20(15) doi: 10.3390/ijms20153663
|
| 85 |
Budhi Singh Yadav, Ankita Gupta, Bhavana Rai, Amanjit Bal. Response to cisplatin in a metastatic triple-negative breast cancer patient. Annals of Oncology Research and Therapy 2021; 1(1) doi: 10.4103/aort.aort_8_21
|
| 86 |
Charles Johannessen, Line Moi, Yury Kiselev, Mona Irene Pedersen, Stig Manfred Dalen, Tonje Braaten, Lill-Tove Busund, Aamir Ahmad. Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. PLOS ONE 2017; 12(10) doi: 10.1371/journal.pone.0186658
|
| 87 |
Fugui Ye, Min He, Liang Huang, Guantian Lang, Xin Hu, Zhimin Shao, Genhong Di, Ayong Cao. Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer. Frontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.574813
|
| 88 |
Cornelia Braicu, Valentina Pileczki, Laura Pop, Roxana Cojocneanu Petric, Sergiu Chira, Eve Pointiere, Patriciu Achimas-Cadariu, Ioana Berindan-Neagoe, Sumitra Deb. Dual Targeted Therapy with p53 siRNA and Epigallocatechingallate in a Triple Negative Breast Cancer Cell Model. PLOS ONE 2015; 10(4) doi: 10.1371/journal.pone.0120936
|
| 89 |
Mohd. Kamil Hussain, Deependra Kumar Singh, Akhilesh Singh, Mohd. Asad, Mohd. Imran Ansari, Mohammad Shameem, Shagun Krishna, Guru R. Valicherla, Vishal Makadia, Sanjeev Meena, Amit Laxmikant Deshmukh, Jiaur R. Gayen, Mohammad Imran Siddiqi, Dipak Datta, Kanchan Hajela, Dibyendu Banerjee. A Novel Benzocoumarin-Stilbene Hybrid as a DNA ligase I inhibitor with in vitro and in vivo anti-tumor activity in breast cancer models. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-10864-3
|
| 90 |
Shuang Li, Qingzhu Wei, Qin Li, Bin Zhang, Qiang Xiao. Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer. Cancer Biology & Therapy 2015; 16(6) doi: 10.1080/15384047.2015.1040958
|
| 91 |
Blessing I Bassey-Archibong, Lyndsay G A Rayner, Shawn M Hercules, Craig W Aarts, Anna Dvorkin-Gheva, Jonathan L Bramson, John A Hassell, Juliet M Daniel. Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. Cell Death & Disease 2017; 8(3) doi: 10.1038/cddis.2017.92
|